3-(3′-pyridyl)-5-(3′-toluyl)-1,2,4-oxadiazole | 388575-86-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(3′-pyridyl)-5-(3′-toluyl)-1,2,4-oxadiazole
• 英文别名: 3-(3-pyridyl)-5-(3-toluyl)-1,2,4-oxadiazole；Cambridge id 5909455；5-(3-methylphenyl)-3-pyridin-3-yl-1,2,4-oxadiazole
• CAS: 388575-86-8
• 化学式: C₁₄H₁₁N₃O
• 分子量: 237.261
• InChiKey: XYXDTQYIMLLEQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氰基吡啶 在 吡啶 、 盐酸羟胺 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 8.0h， 生成 3-(3′-pyridyl)-5-(3′-toluyl)-1,2,4-oxadiazole
  参考文献：
  名称：

  Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening

  摘要：

  Ataluren, also known as PTC124, is a 5-(fluorophenyI)-1,2,4-oxadiazolyl-benzoic acid suggested to suppress nonsense mutations by readthrough of premature stop codons in the mRNA. Potential interaction of PTC124 with mRNA has been recently studied by molecular dynamics simulations highlighting the importance of H-bonding and stacking pi-pi interactions. A series of non-acidic analogues of PTC124 were selected from a large database via a ligand-based virtual screening approach. Eight of them were synthesized and tested for their readthrough activity using the Fluc reporter harboring the UGA premature stop codon. The most active compound was further tested for suppression of the UGA nonsense mutation in the bronchial epithelial IB3.1 cell line carrying the W1282X mutation in the CFTR gene. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.06.048

文献信息

• NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS
  申请人：Roberts Edward

  公开号：US20120329838A1

  公开（公告）日：2012-12-27

  Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

  提供了激活鞘氨醇-1-磷酸受体亚型1的化合物。某些化合物在与鞘氨醇-1-磷酸受体亚型3相比，选择性地激活受体亚型1。提供了使用和方法，用于治疗激活、激动、抑制或拮抗S1P1在医学上指示的疾病的创新化合物。
• US8466183B2
  申请人：——

  公开号：US8466183B2

  公开（公告）日：2013-06-18
• US8481573B2
  申请人：——

  公开号：US8481573B2

  公开（公告）日：2013-07-09
• US8530503B2
  申请人：——

  公开号：US8530503B2

  公开（公告）日：2013-09-10
• US9382217B2
  申请人：——

  公开号：US9382217B2

  公开（公告）日：2016-07-05